Kashif Irshad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kashif Irshad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Beharry
Department of Laboratory Medicine, William Osler Health System, Brampton, ON L6R 3J7, Canada
1 shared publication - Anna M. Bendzsak
Osler Research Institute for Health Innovation, William Osler Health System, Brampton, ON L6R 3J7, Canada
1 shared publication - Brandon S. Sheffield
William Osler Health System, Brampton, ON L6R 3J7, Canada
1 shared publication - Champica Nicholas
Division of Advanced Diagnostics, William Osler Health System, Brampton, ON L6R 3J7, Canada
1 shared publication - Ching Yeung
Osler Research Institute for Health Innovation, William Osler Health System, Brampton, ON L6R 3J7, Canada
1 shared publication - David Chun Cheong Tsui
Osler Research Institute for Health Innovation, William Osler Health System, Brampton, ON L6R 3J7, Canada
1 shared publication
Latest Publications
- Open Access
Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center
Liquid biopsy is rapidly becoming an indispensable tool in the oncologist’s arsenal; however, this technique remains elusive in a publicly funded healthcare system, and real-world evidence is needed to demonstrate utility and feasibility. Here, we describe the first experience of an in-house point of care liquid biopsy program at a Canadian community hospital. A retrospective review of consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. Liquid biopsy was initiated at the discretion of clinicians. Sequencing followed a point of care workflow using the Genexus™ integrated sequencer and the Oncomine precision assay, performed by histotechnologists. Results were reported by the attending pathologist. Eligible charts were reviewed for outcomes of interest, including the intent of the liquid biopsy, results of the liquid biopsy, and turnaround time from blood draw to results available. A total of 124 cases, with confirmed or suspected cancer, underwent liquid biopsy between January 2021 and November 2023. The median turnaround time for liquid biopsy results was 3 business days (range 1–12 days). The sensitivity of liquid biopsies was 71%, compared to tissue testing in cases with matched tissue results available for comparison. Common mutations included EGFR (29%), in 86 lung cancer patients, and PIK3CA (22%), identified in 13 breast cancer patients. Healthcare providers ordered liquid biopsies to inform diagnostic investigations and treatment decisions, and to determine progression or resistance mechanisms, as these reasons often overlapped. This study demonstrates that rapid in-house liquid biopsy using point of care methodology is feasible. The technique facilitates precision treatment and offers many additional advantages for cancer care.
Open AccessPoint of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center
Liquid biopsy is rapidly becoming an indispensable tool in the oncologist’s arsenal; however, this technique remains elusive in a publicly funded healthcare system, and real-world evidence is needed to demonstrate utility and feasibility. Here, we describe the first experience of an in-house point of care liquid biopsy program at a Canadian community hospital. A retrospective review of consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. Liquid biopsy was initiated at the discretion of clinicians. Sequencing followed a point of care workflow using the Genexus™ integrated sequencer and the Oncomine precision assay, performed by histotechnologists. Results were reported by the attending pathologist. Eligible charts were reviewed for outcomes of interest, including the intent of the liquid biopsy, results of the liquid biopsy, and turnaround time from blood draw to results available. A total of 124 cases, with confirmed or suspected cancer, underwent liquid biopsy between January 2021 and November 2023. The median turnaround time for liquid biopsy results was 3 business days (range 1–12 days). The sensitivity of liquid biopsies was 71%, compared to tissue testing in cases with matched tissue results available for comparison. Common mutations included EGFR (29%), in 86 lung cancer patients, and PIK3CA (22%), identified in 13 breast cancer patients. Healthcare providers ordered liquid biopsies to inform diagnostic investigations and treatment decisions, and to determine progression or resistance mechanisms, as these reasons often overlapped. This study demonstrates that rapid in-house liquid biopsy using point of care methodology is feasible. The technique facilitates precision treatment and offers many additional advantages for cancer care.